

FIG. 1




FIG. 2




FIG. 3

FIG. 3




FIG. 4




FIG. 5

0306 6364660




FIG. 6

Experimental Protocol





Figure 7



Tumor Volume in Bone



EFFECT OF PS/2 mAb TREATMENT ON SPLEEN WEIGHT




Figure 10

EFFECT OF PS/2 TREATMENT ON SPLENOCYTES
IN MICE WITH 5TGM1 MYELOMA





Figure 11

EFFECT OF PS/2 mAb TREATMENT ON SPLENOCYTE FACS PROFILE

DISEASE FREE




File: do111700.077
Gate: G1
Total Events: 10707

Acquisition Date: 17-Nov-00
Gated Events: 9624
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	9499	98.70	88.72	37.11	1120.67
UR	3	0.03	0.03	5084.96	773.52
LL	122	1.27	1.14	31.88	11.09
LR	0	0.00	0.00

UNTREATED




File: do111700.100
Gate: G1
Total Events: 11100

Acquisition Date: 17-Nov-00
Gated Events: 9528
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4959	52.06	44.68	84.30	1023.41
UR	1388	14.57	12.50	2377.81	704.20
LL	2163	22.71	19.49	50.53	6.84
LR	1016	10.67	9.15	3619.03	4.05

PS/2 TREATED




File: do111700.120
Gate: G1
Total Events: 10934

Acquisition Date: 17-Nov-00
Gated Events: 9561
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	7868	82.29	71.96	58.00	1139.33
UR	310	3.24	2.84	1922.82	897.47
LL	1171	12.25	10.71	42.10	8.17
LR	212	2.22	1.94	3153.17	3.62

rat IgG2b TREATED



File: do111700.137
Gate: G1
Total Events: 10970

Acquisition Date: 17-Nov-00
Gated Events: 9595
Quad Location: 523, 25

Quad	Events	% Gated	% Total	X Mean	Y Mean
UL	4910	51.17	44.76	84.95	975.19
UR	1384	14.42	12.62	1937.36	694.49
LL	1704	17.76	15.53	48.67	7.00
LR	1597	16.64	14.56	3286.15	2.68

Figure 12

103027 09924600

EFFECT OF PS/2 mAb TREATMENT ON SPEEN TUMOR BURDEN




Figure 13

EFFECT OF PS/2 mAB TREATMENT ON BONE MARROW CELLS IN MICE WITH 5TGM1 MYELOMA




Figure 14

EFFECT OF PS/2 TREATMENT ON BONE MARROW TUMOR BURDEN
mIgG2b POSITIVE CELLS




Figure 15

EFFECT OF PS/2 mAb TREATMENT ON 5TGM1 CELLS IN THE BLOOD




Figure 16

EFFECT OF PS/2 TREATMENT ON BLOOD CHEMISTRY




Figure 17

EFFECT OF PS/2 mAb ON
CIRCULATION mIgG2b LEVELS




Figure 18

1 (200 microgram) PS/2 TREATMENT / 1 DAY N=3/GROUP

day

0 7 14 16 17

↑

2 (200 microgram) PS/2 TREATMENTS/ 2 DAYS N=3/GROUP

day

0 7 14 16 17 18

↑ ↑

6 (200 microgram) PS/2 TREATMENTS/6 DAYS N=5/GROUP

day

0 7 14 15 16 17 18 19 20

↑ ↑ ↑ ↑ ↑

Figure 19

EFFECT OF PS/2 TREATMENT ON IgG2b POSITIVE CELLS
ACUTE TREATMENT MODEL




Figure 20

EFFECT OF ANTI VLA-4 ANTIBODY PS/2 ON TUMOR BURDEN IN SPLEEN




Figure 21

EFFECT OF 6 DAYS OF PS/2 TREATMENT




Figure 22

EFFECT OF 6 DAYS OF PS/2 TREATMENT ON BONE MARROW CELLS





Figure 23

C57/BlK^aL^wR^aJ MODEL OF MULTIPLE MYELOMA COMBINATION TREATMENT WITH PS/2 AND MELPAHLAN



STGM1 CELLS (1E6) WERE INJECTED (I.V.) ON DAY 0
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20 AND DAY 27

GROUPS N=3/GROUP

- DISEASE FREE CONTROL
- UNTREATED MYELOMA CONTROL
- MELPHALAN TREATMENT --100 MICROGRAMS/INJECTION
- PS/2 TREATMENT --100 MICROGRAMS/INJECTION
- MELPHALAN AND PS/2
- MELPAHLAN AND rIgG2b ISOTYPE CONTROL

Figure 24

EFFECT OF TREATMENT ON mIgG2b PLASMA LEVELS




Figure 25

Figure 26

EFFECT OF TREATMENT ON TUMOR BURDEN AT DAY 27





Figure 27

	Day 20	day 27
	PS/2 Plasma levels	PS/2 Plasma levels
8-PS/2	none detected	none detected
9-PS/2	none detected	none detected
10-PS/2	none detected	none detected
11-melphalan+PS/2	none detected	none detected
12-melphalan+PS/2	3.7 μ g/ml	none detected
13-melphalan+PS/2	none detected	none detected

Figure 28

09/943,659

**C57/BIK_aL_wRaj MODEL OF MULTIPLE MYELOMA
 PS/2 AND ANTI VLA4 SMALL MOLECULE
 LONG TERM TREATMENT**



5TGM1 CELLS (1B6) INJECTED(I.V.) ON DAY 0
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 20

GROUPS N=2/GROUP
 DISEASE FREE CONTROL
 UNTREATED MYELOMA CONTROL
 PS/2 --100 micrograms/injection
 Sm. Mol. 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
 Sm. Mol. 9257 CONTROL -- 3 mg/kg

Figure 29

EFFECT OF LONG TERM TREATMENT ON MYELOMA CELLS




Figure 30

EFFECT OF LONG TERM TREATMENT ON TUMOR BURDEN





Figure 31

FIGURE 31

C57/BIK_aLwRaj MODEL OF MULTIPLE MYELOMA
 PS/2 AND ANTI VLA4 SMALL MOLECULE
 ACUTE TREATMENT



5TGM1 CELLS (1E6) INJECTED(I.V.) ON DAY 0
 PS/2 WAS GIVEN ON DAYS 15,16,17,18,19 AND 20
 SMALL MOLECULE WAS GIVEN ON DAYS 15, 16 AND 17
 EFFECTIVENESS OF TREATMENT WAS EVALUATED ON DAY 21

GROUPS N=2/GROUP
 DISEASE FREE CONTROL
 UNTREATED MYELOMA CONTROL
 PS/2 --100 micrograms/injection
 8809--3 mg/kg, 0.3 mg/kg or 0.03 mg/kg
 9257 CONTROL -- 3 mg/kg

Figure 32

EFFECT OF ACUTE TREATMENT ON MYELOMA CELLS




Figure 33

EFFECT OF ACUTE TREATMENT ON TUMOR BUREN




Figure 34

Experimental Protocol

5TGM1 Cells (10⁶/mouse)




Figure 35

Inhibition of Hindleg Paralysis




Figure 36